Want to see VANI full AI Analyst Report?
VANI Stock Chart & Stats
$1.42
$0.02(1.56%)
At close: 4:00 PM EDT
$1.42
$0.02(1.56%)
Day’s Range― - ―
52-Week Range$0.92 - $1.92
Previous CloseN/A
Volume59.57K
Average Volume (3M)171.88K
Market Cap
$128.09M
Enterprise Value$105.99
Total Cash (Recent Filing)$19.89M
Total Debt (Recent Filing)$17.86M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 18, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding90,203,354
10 Day Avg. Volume157,627
30 Day Avg. Volume171,877
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.83Price Target Upside169.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ExecutionCompleting the lead obesity trial ahead of schedule demonstrates operational execution and advances NPM-139 toward top-line data, an IND filing and planned Phase 2 development, creating a clearer path for clinical validation.
Platform ValidationEvaluation by a major GLP-1 developer provides external validation for Vivani’s implant approach and could improve future partnering potential, although the agreement does not yet establish commercial revenue or product rights.
Cost DisciplineLower operating expenses and a narrower quarterly loss indicate some progress in spending control. Sustained discipline could extend available resources and improve development efficiency while the company remains pre-commercial.
Bears Say
No Commercial RevenueThe absence of revenue confirms that Vivani has not yet commercialized a product and lacks operating leverage. Continued dependence on clinical progress leaves financial performance vulnerable to trial delays or unsuccessful development.
Persistent Cash BurnLarge recurring cash outflows consume resources before any product revenue is available. This raises the likelihood of additional financing and means clinical execution must continue successfully to preserve the company’s development capacity.
Balance Sheet RiskDebt approaching the level of equity reduces financial flexibility for a clinical-stage company with continuing losses. Additional capital needs could increase financing costs or dilution and constrain investment in the pipeline.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.92 and its highest was $1.92 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $128.09M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Nov 18, 2026 which is in 74 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Aug 13, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.083 by $0.013.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.08.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 90,203,354 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.083. Following the earnings report the stock price went up 4.478%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (169.95% Upside)
$3.83 (169.95% Upside)
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.0%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
VANI Stock 12 Month Forecast
Average Price Target
$3.83
▲(169.95% Upside)
Technical Analysis
Ownership Overview
50.63% Insiders
2.19% Mutual Funds
0.93% Other Institutional Investors
44.17% Public Companies and
Individual Investors